Cerenome, Inc. (CNSY)
NASDAQ: CNSY · Real-Time Price · USD
3.690
-0.010 (-0.27%)
Aug 14, 2026, 3:08 PM EDT - Market open
Cerenome Employees
Cerenome had 28 employees as of December 31, 2025. The number of employees increased by 7 or 33.33% compared to the previous year.
Employees
28
Change (1Y)
7
Growth (1Y)
33.33%
Revenue / Employee
$185,071
Profits / Employee
-$426,107
Market Cap
25.40M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 28 | 7 | 33.33% |
| Dec 31, 2024 | 21 | 1 | 5.00% |
| Dec 31, 2023 | 20 | 3 | 17.65% |
| Dec 31, 2022 | 17 | 3 | 21.43% |
| Dec 31, 2021 | 14 | 2 | 16.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evaxion | 46 |
| Longeveron | 38 |
| Jasper Therapeutics | 22 |
| ABVC BioPharma | 19 |
| Tevogen | 18 |
| Atossa Therapeutics | 16 |
| Barinthus Biotherapeutics | 14 |
| Actuate Therapeutics | 12 |
CNSY News
- 1 day ago - Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives - GlobeNewsWire
- 14 days ago - Cerenome Launches as an Integrated CNS Oncology Company - GlobeNewsWire
- 17 days ago - Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference - GlobeNewsWire
- 24 days ago - Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding - GlobeNewsWire
- 7 weeks ago - Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - GlobeNewsWire